# A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

> **NCT04888949** · PHASE2 · COMPLETED · sponsor: **Rohto Pharmaceutical Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- SARS-CoV-2 Infection( COVID-19 )

## Interventions

- **BIOLOGICAL:** Mesenchymal stem cell
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04888949
- **Lead sponsor:** Rohto Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-05-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04888949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04888949, "A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04888949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*